Could Low-Dose Radiation Therapy Expand The Future Of Radiation Medicine?

Radiation therapy is widely established as an important component of modern cancer treatment. However, emerging research is also exploring its potential applications beyond oncology, including the management of inflammatory and degenerative conditions. 

New findings presented by the Amerikanische Gesellschaft für Radioonkologie (ASTRO) in September 2026 suggest that low-dose radiation therapy could have a longer-term role in managing early knee osteoarthritis.

The research highlights an important area of innovation for the wider radiation medicine sector: understanding how different radiation doses interact with biological processes, and whether established treatment technologies could have applications beyond their traditional uses.

Exploring radiation therapy beyond cancer treatment

Radiotherapy is most commonly associated with cancer treatment, where carefully controlled doses of ionising radiation are used to damage cancer cells and prevent their growth. However, radiotherapy technology encompasses a broader range of applications.

Low-dose radiation therapy (LDRT) has been used for decades in parts of Europe to manage certain benign inflammatory conditions, including osteoarthritis. 

Unlike the higher doses used in cancer treatment, LDRT aims to influence inflammatory processes within affected tissues. Inflammation is an important component of Arthrose, a degenerative joint condition involving changes to cartilage, bone and other structures. 

While conventional management approaches can help relieve symptoms and improve mobility, there remains a need for treatments that may also influence the underlying progression of the disease.

This is the question addressed by the latest research presented at ASTRO’s 2026 Annual Meeting.

What did the latest osteoarthritis study find?

The study, reported by ASTRO in September 2026, examined long-term outcomes from a randomised trial involving 292 patients with symptomatic knee osteoarthritis.

Participants were assigned to receive either glucosamine and chondroitin alone or the same medication alongside low-dose radiation therapy. The radiotherapy group received a total dose of 4.5 Gy across ten treatment sessions.

Researchers assessed pain, physical function and quality of life, alongside changes in joint structure using magnetic resonance imaging (MRI). They also examined longer-term outcomes, including disability and knee replacement, using regional health records.

The findings indicated that patients receiving low-dose radiation therapy experienced more sustained improvements in pain, physical function and quality of life than those receiving medication alone.

MRI assessments also identified significantly less structural deterioration in the radiotherapy group over three years. 

During a median follow-up period of almost 12 years, low-dose radiation therapy was associated with a 67 per cent lower adjusted hazard of government-certified disability due to knee osteoarthritis.

The findings were particularly notable among patients with grade 2 osteoarthritis. Within this subgroup, disability occurred in 31 per cent of those receiving radiotherapy, compared with 61 per cent in the medication-only group. 

Knee replacements were recorded in 14 per cent and 36 per cent respectively. These results raise the possibility that low-dose radiation therapy could influence disease progression rather than simply providing temporary symptom relief.

Gopal K. Bajaj, Co-chair of ASTRO’s Functional Radiation Medicine Task Force and a radiation oncologist at Inova Schar Cancer Institute in Fairfax, Va. commented:

“For osteoarthritis, we have treatments that can help patients feel better, but much less evidence that they can change what is happening inside the joint. What makes these findings interesting is that the patient-reported improvement was accompanied by a measurable difference on MRI.”

“That moves the question beyond pain relief alone. The long-term disability data add another reason to test whether low-dose radiation can affect the course of early osteoarthritis in a larger, rigorously controlled trial.”

Why further research is essential

Although the findings are encouraging, the researchers have emphasised the need for further investigation before conclusions can be drawn about the treatment’s wider clinical application.

The original trial was conducted at a single institution in Russia, and participants knew whether they were receiving radiation therapy. The control group did not receive simulated radiotherapy, while some of the longer-term findings were exploratory.

A separate multicentre, randomised, sham-controlled trial published in BMC Medicine in October 2026 also illustrates the importance of continued evaluation. 

This study found a significant short-term improvement in treatment response with a 3 Gy regimen, but did not demonstrate consistent differences across several secondary clinical and imaging measures.

Together, these findings underline the need for larger, well-controlled studies to establish which patients might benefit, the most appropriate treatment protocols and the longer-term safety profile.

This is particularly important when considering radiation exposure in younger populations, where potential long-term risks require careful assessment.

What does this mean for the future of radiation medicine?

Research into low-dose radiation therapy reflects a wider shift towards investigating the biological effects of radiation across different clinical applications.

For the radiation oncology sector, this creates opportunities for scientific collaboration, technological development and further investigation into how radiation can be used safely and effectively.

It also highlights the importance of distinguishing between different treatment applications. The biological mechanisms, dose requirements and clinical objectives of low-dose radiation for inflammatory conditions are fundamentally different from those involved in treating malignant disease.

Nevertheless, developments in imaging, treatment planning, radiation delivery and quality assurance have relevance across the wider field of radiation medicine. 

Continued technological progress and clinical research will be important in determining how emerging applications can be translated into established practice.

For healthcare organisations, this also raises strategic questions about investment in specialist expertise, research partnerships and the infrastructure required to evaluate new treatment approaches responsibly.

Evidence-led innovation in radiation oncology

The latest ASTRO findings demonstrate why continued research into radiation medicine matters. 

While low-dose radiation therapy for knee osteoarthritis remains an area requiring further clinical validation, the results provide an interesting example of how established technologies can be investigated in new contexts.

For Stingray Healthcare Group, innovation in radiation oncology involves more than adopting new equipment or expanding existing treatment capabilities. 

It also requires engagement with scientific developments, collaboration between specialists and a commitment to evaluating emerging evidence. As research advances, the boundaries of radiation medicine may continue to evolve. 

Mehr über erfahren Stingray Healthcare Group and its commitment to innovation, clinical collaboration and the development of specialist radiation services across Europe.